You are here

A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms, Neoplasm Metastasis
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Signed written and voluntary informed consent

- Histologically or cytologically confirmed breast cancer

- Stage IV (metastatic) breast cancer

- Biopsy (fresh or archival) of primary breast cancer or metastatic site demonstrating
HER2 gene amplification as determined in study-specified central laboratory by
fluorescence in situ hybridization (FISH)

- Prior treatment and progressive disease with at least 1 but not more than 2 cytotoxic
chemotherapy regimen(s) for metastatic disease

- Those for whom the use of an investigational HER2 inhibitor is appropriate because
they do not have access to approved HER2 inhibitors (e.g., Herceptin®) or for whom
treatment with currently available HER2 inhibitors is inappropriate

- Limited visceral disease burden (i.e., disease-related symptoms (i.e., well controlled with supportive care measures)

- Presence of at least one measurable target lesion [i.e., malignant tumor mass that can
be accurately measured in at least 1 dimension of >=2 cm with conventional
radiographic techniques or magnetic resonance imaging, or >=1 cm with spiral CT scan
as per RECIST], excluding previously irradiated lesions, bone metastasis or pleural
effusion as sole manifestations of disease. If the measurable disease is restricted to
a solitary lesion, its neoplastic nature must be confirmed by cytology/histology

- Eastern Cooperative Oncology Group (ECOG) performance status 0 1

- Patient available for treatment, monitoring, and follow-up. Willing and able to comply
with scheduled visits, therapy plan, laboratory tests and blood sampling for
pharmacokinetic (PK) analyses

- Recovery to baseline or NCI CTCAE Version 3.0 Grade 1 toxicity from all acute effects
related to prior treatment, except alopecia

- Adequate Bone Marrow Function, including: a. Absolute neutrophil count (ANC) >=1500
cells/mm3; b. Platelets >=100,000 cells/mm3

- Adequate Renal Function, including: a. Estimated creatinine clearance >=60 mL/min; b.
SrCr

- Adequate Liver Function, including: a. Bilirubin (SGOT)

- Adequate Cardiac Function, including: a. 12-Lead electrocardiogram (ECG) with normal
tracing or non clinically significant changes that do not require medical
intervention; b. QTc interval or other symptomatic QTc abnormality; c. Left ventricular ejection fraction (LVEF) >=
institutional lower limit of normal and 45% as measured by echocardiogram or multi
gated radionuclide angiography (MUGA) within 4 weeks prior to start of study treatment

- >= 18 years old

- Female

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Women of child-bearing potential who are unwilling or unable to use an acceptable
method to avoid pregnancy for the entire study period and up to 4 weeks after study

- Women who are pregnant or breastfeeding

- Women with a positive pregnancy test on enrollment or within 72 hours prior to study
drug administration

- Prior treatment with trastuzumab (Herceptin®) or other HER2-targeting agents [e.g.,
lapatinib (GW572016), pertuzumab (Omnitarg?; rhuMab 2C4), CI 1033, EKB 569, CP
724,714]

- Cumulative dose >450 mg/m2 of doxorubicin or doxorubicin equivalents

- Prior high-dose chemotherapy requiring hematopoetic stem cell transplantation within
12 months of study treatment start

- Radiotherapy, investigational chemotherapy, biologic therapy within 4 weeks of study
treatment start

- Previous (within the last 5 years) or current malignancies arising from sites other
than breast, except for adequately treated basal cell or squamous cell skin cancer or
in situ carcinoma of the cervix uteri

- Known or clinically suspected brain metastasis or leptomeningeal disease (no screening
CT scan required) requiring therapy. Patients with asymptomatic previously treated CNS
metastases that no longer require therapy or corticosteroids/anticonvulsants for at
least 4 weeks prior to start of study treatment are eligible

- Any clinically significant gastrointestinal abnormalities, which may impair intake,
transit or absorption of the study drug, such as the inability to take oral medication
in tablet form, prior complete/partial gastrectomy or intestinal resection, or a
requirement for H2 antagonists or proton pump inhibitors

- Any mental disorder that would limit the understanding or rendering of informed
consent and/or compromise compliance with the requirements of this protocol

- Uncontrolled or significant cardiovascular disease, including: a. Myocardial
infarction within 12 months; b. Uncontrolled angina within 6 months; c. Congestive
heart failure within 6 months or left ventricular ejection fraction below local
institutional lower limit of normal or below 45%; d. Diagnosed or suspected congenital
long QT syndrome; e. Any history of clinically significant ventricular arrhythmias
(such as ventricular tachycardia, ventricular fibrillation, or torsade de pointes); f.
Prolonged QTc interval on pre-entry electrocardiogram (>450 msec); g. Any history of
second or third degree heart block (may be eligible if currently have a pacemaker); h.
Heart rate

- History of drug-induced hyperbilirubinemia

- Concurrent treatment with approved or investigational chemotherapy, hormonal therapy,
immunotherapy, or radiotherapy (hormone replacement therapy is permitted)

- Concurrent treatment with H2 antagonists and/or proton pump inhibitors. However, H2
antagonists can be used for the treatment of an unexpected hypersensitivity reaction
during the study period. Antacids are allowed but only up to 2 hours before and 2
hours after study drug administration

- Concurrent treatment or treatment within 4 weeks of first dose with potent and/or
irreversible CYP3A4 inhibitors including: ketoconazole, itraconazole, troleandomycin,
clarithromycin, erythromycin, ritonavir, indinavir, nelfinavir, saquinavir,
nefazodone, mibefradil, amiodarone and grapefruit juice

- Concurrent treatment or treatment within 4 weeks of first dose with potent inducers of
CYP3A4 including: rifampin, rifabutin, rifamycins, phenytoin, barbiturates,
carbamazepine, glucocorticoids, modafinil, phenobarbital, troglitazone, pioglitazone,
efavirenz, nevirapine, dexamethasone, and St. John's wort

- Prisoners or patients who are compulsorily detained or involuntarily incarcerated
(e.g., for treatment of infectious disease, psychiatric illness, etc.)

NCT00102895
Pfizer
Terminated
A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Breast Neoplasm
NCT03445637
Females
18+
Years
Seoul,
Ovarian Cancer HR+ HER2- Metastatic Breast Cancer
NCT03519178
All Genders
18+
Years
Multiple Sites
Breast Neoplasms
NCT01176916
Females
0+
Years
Multiple Sites
Breast Neoplasms
NCT00174434
All Genders
18+
Years
Multiple Sites
A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer
An Open-Label, Multi-Center, Phase 2 Study Of Cp 724,714 In Patients With Her2 Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy For Metastatic Disease And Is Previously Untreated With A Her2 Inhibitor

The main purpose of this research study is to see if the study drug, named CP-724,714, can help in the treatment of certain breast cancers that have spread to other locations in the body. Other goals of this study are to measure how long it may take for the cancer to get worse (progress), to see if there are any side effects from the study drug, to check the amount of study drug in the blood at different times, and to check to see if there is any relationship between certain blood tests and how patients may respond to the study drug.

About 25 subjects at 4 sites (hospitals and clinics) in Bulgaria and Russia will be involved in the trial. Participation in this study can last up to 48 weeks, depending on the participant's toleration of the study drug and the response of her tumor(s) to the study drug. All participants will receive CP-724,714, at a daily dose of 250 mg (4 pills) every 12 hours.

Pfizer decided to terminate clinical protocol A4031003 on October 7, 2005 due to the excessive number of patients with grade 3 liver function test elevations and lack of efficacy.
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Breast Neoplasms
  • Neoplasm Metastasis
Drug: CP-724,714
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
25
September 2005
Not Provided

Inclusion Criteria:

  • Signed written and voluntary informed consent
  • Histologically or cytologically confirmed breast cancer
  • Stage IV (metastatic) breast cancer
  • Biopsy (fresh or archival) of primary breast cancer or metastatic site demonstrating HER2 gene amplification as determined in study-specified central laboratory by fluorescence in situ hybridization (FISH)
  • Prior treatment and progressive disease with at least 1 but not more than 2 cytotoxic chemotherapy regimen(s) for metastatic disease
  • Those for whom the use of an investigational HER2 inhibitor is appropriate because they do not have access to approved HER2 inhibitors (e.g., Herceptin®) or for whom treatment with currently available HER2 inhibitors is inappropriate
  • Limited visceral disease burden (i.e., <30% involvement of any organ) and limited disease-related symptoms (i.e., well controlled with supportive care measures)
  • Presence of at least one measurable target lesion [i.e., malignant tumor mass that can be accurately measured in at least 1 dimension of >=2 cm with conventional radiographic techniques or magnetic resonance imaging, or >=1 cm with spiral CT scan as per RECIST], excluding previously irradiated lesions, bone metastasis or pleural effusion as sole manifestations of disease. If the measurable disease is restricted to a solitary lesion, its neoplastic nature must be confirmed by cytology/histology
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 1
  • Patient available for treatment, monitoring, and follow-up. Willing and able to comply with scheduled visits, therapy plan, laboratory tests and blood sampling for pharmacokinetic (PK) analyses
  • Recovery to baseline or NCI CTCAE Version 3.0 Grade 1 toxicity from all acute effects related to prior treatment, except alopecia
  • Adequate Bone Marrow Function, including: a. Absolute neutrophil count (ANC) >=1500 cells/mm3; b. Platelets >=100,000 cells/mm3
  • Adequate Renal Function, including: a. Estimated creatinine clearance >=60 mL/min; b. SrCr <1.5 x ULN
  • Adequate Liver Function, including: a. Bilirubin <=ULN (upper limit of normal); b. AST (SGOT) <=2.5 x ULN; c. ALT (SGPT) <=2.5 x ULN
  • Adequate Cardiac Function, including: a. 12-Lead electrocardiogram (ECG) with normal tracing or non clinically significant changes that do not require medical intervention; b. QTc interval <=450 msec and without history of Torsades des Pointes or other symptomatic QTc abnormality; c. Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal and 45% as measured by echocardiogram or multi gated radionuclide angiography (MUGA) within 4 weeks prior to start of study treatment
  • >= 18 years old
  • Female

Exclusion Criteria:

  • Women of child-bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and up to 4 weeks after study
  • Women who are pregnant or breastfeeding
  • Women with a positive pregnancy test on enrollment or within 72 hours prior to study drug administration
  • Prior treatment with trastuzumab (Herceptin®) or other HER2-targeting agents [e.g., lapatinib (GW572016), pertuzumab (Omnitarg?; rhuMab 2C4), CI 1033, EKB 569, CP 724,714]
  • Cumulative dose >450 mg/m2 of doxorubicin or doxorubicin equivalents
  • Prior high-dose chemotherapy requiring hematopoetic stem cell transplantation within 12 months of study treatment start
  • Radiotherapy, investigational chemotherapy, biologic therapy within 4 weeks of study treatment start
  • Previous (within the last 5 years) or current malignancies arising from sites other than breast, except for adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri
  • Known or clinically suspected brain metastasis or leptomeningeal disease (no screening CT scan required) requiring therapy. Patients with asymptomatic previously treated CNS metastases that no longer require therapy or corticosteroids/anticonvulsants for at least 4 weeks prior to start of study treatment are eligible
  • Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of the study drug, such as the inability to take oral medication in tablet form, prior complete/partial gastrectomy or intestinal resection, or a requirement for H2 antagonists or proton pump inhibitors
  • Any mental disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this protocol
  • Uncontrolled or significant cardiovascular disease, including: a. Myocardial infarction within 12 months; b. Uncontrolled angina within 6 months; c. Congestive heart failure within 6 months or left ventricular ejection fraction below local institutional lower limit of normal or below 45%; d. Diagnosed or suspected congenital long QT syndrome; e. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsade de pointes); f. Prolonged QTc interval on pre-entry electrocardiogram (>450 msec); g. Any history of second or third degree heart block (may be eligible if currently have a pacemaker); h. Heart rate <50/minute on pre-entry electrocardiogram; i. Uncontrolled hypertension
  • History of drug-induced hyperbilirubinemia
  • Concurrent treatment with approved or investigational chemotherapy, hormonal therapy, immunotherapy, or radiotherapy (hormone replacement therapy is permitted)
  • Concurrent treatment with H2 antagonists and/or proton pump inhibitors. However, H2 antagonists can be used for the treatment of an unexpected hypersensitivity reaction during the study period. Antacids are allowed but only up to 2 hours before and 2 hours after study drug administration
  • Concurrent treatment or treatment within 4 weeks of first dose with potent and/or irreversible CYP3A4 inhibitors including: ketoconazole, itraconazole, troleandomycin, clarithromycin, erythromycin, ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, mibefradil, amiodarone and grapefruit juice
  • Concurrent treatment or treatment within 4 weeks of first dose with potent inducers of CYP3A4 including: rifampin, rifabutin, rifamycins, phenytoin, barbiturates, carbamazepine, glucocorticoids, modafinil, phenobarbital, troglitazone, pioglitazone, efavirenz, nevirapine, dexamethasone, and St. John's wort
  • Prisoners or patients who are compulsorily detained or involuntarily incarcerated (e.g., for treatment of infectious disease, psychiatric illness, etc.)
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Bulgaria,   Russian Federation
 
NCT00102895
A4031003
Not Provided
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
August 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now